New Delhi: The country is still in the midst of a corona epidemic terror, while the Central Institute of Pharmaceutical Research (CDRI), Lucknow has claimed to have made Umifenovir, an indigenous drug of COVID. According to the institute, the clinical trial of the third round of the antiviral drug has been successful. The institute says that Umifenovir is very effective in treating light and symptomless patients of corona and is beneficial as prophylactic for high-risk patients. It will completely eliminate the viral load in five days.
The same CDRI Director Prof. Tapas Kundu said that the Controller General of Medicines, Government of India (DCGI) had in June last year allowed the CDRI to undergo the third phase of clinical examination on symptomless, mild and moderate corona patients with the help of KGMU, Era Lucknow Medical College and Hospital and Ram Manohar Lohia Institute of Medical Sciences. CSIR had suggested 16 medicines, out of which Umifenovir (Arbidol) was selected for the trial.
As well Director Prof. Kundu said Umifenovir is a medicine. It is also being developed as syrup and inhaler. He said the investigation also involved patients who had obtained delta variant of the virus. It is said to be effective on delta variants as well. He said 132 patients were given clinical examination. The Director said that Umifenovir sars eliminates the cell culture of Covid-19 in a very effective manner.